Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference. In a report, the bank said big pharmas are looking for deals involving de-risked assets.
Skip Kelly, a managing director at J.P. Morgan, provides a broad overview of how the healthcare investment landscape is shaping up in the midst of a historic pandemic, as part of MedCity's 2021 INVEST conference.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
As early stage, high-growth startups prepare for the future, venture capital and partnerships will look different but opportunity is still out there.
In an interview, Peter Meath, J.P. Morgan’s co-head of Healthcare and Life Sciences, Middle Market Banking & Specialized Industries, says the Covid-19 pandemic has cast a bright light on the life sciences industry with startups raising venture funding at record levels as the virus has transformed the way people usually do business in the sector.
Scenario planning and lessons learned from past downturns can help leadership teams guide their startups through an uncertain economy.
Pamela Aldsworth, head of VC coverage and managing director at J.P. Morgan, discusses deals and dealmaking during the pandemic and how startups can survive, in a special presentation to mark MedCity News' annual INVEST conference.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
According to a CNBC report, Haven's latest executive addition is Sandhya Rao, who will serve as the organization's VP of Clinical Strategy.
During an event Rock Health Summit in San Francisco, the always quotable Cosgrove shared his thoughts on topics ranging from the V.A. to Theranos to EMRs to where he believed big tech firms can hope to change healthcare.
The filing comes one week after the company, founded earlier this year with a $300 million Series A round by two former Kite executives, raised $120 million in a private financing.
The company, which has already raised more than $500 million in venture capital funding, would trade on the NASDAQ under the ticker symbol "GH."
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Many industry experts are expressing doubts about the Amazon/Berkshire/JP Morgan healthcare initiative, but large employers who self-insure their employee benefits have historically been at the forefront of adopting new innovations.
Peter Meath, Managing Director and Head of Life Sciences for J.P. Morgan’s Commercial Banking business, shared his perspective on what will happen in the biopharma industry in 2018.
A top J.P. Morgan investment banker has jumped ship and will now carry the flag for healthcare.
Also, we talk Meaningful Use and about the New England Journal of Medicine's opinion that we should pursue a "patient-driven health information economy"